CTNNB1 and malignant colon neoplasm: Subsequent combination studies revealed synergic interaction between trametinib and ICG-001 (Fig 8) in the CTNNB1-wild type SW620 colon cancer cell line and not in the CTNNB1-mutant colon cancer line SW48 (Fig 8).